Experimental ADHD Drug Shows Promise in Early Trial
In a Phase 1b study, the investigational orexin-2 agonist ALKS 7290 improved adult ADHD symptoms within 14 days and had a tolerable safety profile. The results establish clinical proof-of-concept and support advancing the drug to Phase 2 trials.
This early-stage trial marks a notable step in ADHD research, as the drug targets the orexin system—a pathway more commonly associated with wakefulness and arousal than with attention regulation. The reported improvement in symptoms within two weeks, alongside a tolerable safety profile, offers preliminary evidence that this mechanism may hold therapeutic value. Because the findings come from a Phase 1b study, they primarily establish safety and biological activity rather than definitive efficacy. The move toward Phase 2 trials will be crucial for determining whether these early signals translate into meaningful, lasting benefits for patients who often face limited treatment options.
If confirmed in later trials, this drug could offer an alternative for adults with ADHD who do not respond well to existing stimulant or non-stimulant therapies. Its rapid onset of action may improve daily functioning and quality of life for patients, while a distinct mechanism could reduce reliance on controlled substances. However, early results are far from conclusive, and broader impacts—on prescribing practices, patient access, or healthcare costs—will depend on larger studies and regulatory review.